rel-(R,R)-Voriconazole suppliers
rel-(R,R)-Voriconazole
- CAS:
- 137330-52-0
- MF:
- C16H14F3N5O
- MW:
- 349.31
Suppliers by country/region
Company Type
Properties
- Boiling point:
- 508.6±60.0 °C(Predicted)
- Density
- 1.42±0.1 g/cm3(Predicted)
- storage temp.
- 2-8°C, sealed storage, away from moisture
- solubility
- Chloroform (Slightly), Methanol (Slightly, Sonicated)
- form
- Solid
- pka
- 11.54±0.29(Predicted)
- color
- White to Off-White
- InChI
- InChI=1/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16-/s3
- InChIKey
- BCEHBSKCWLPMDN-OHNRHGLTNA-N
- SMILES
- C([n]1ncnc1)[C@@](O)(c1ccc(F)cc1F)[C@@H](C)c1c(F)cncn1 |&1:6,16,r|
Safety Information
Use
The (R,R)-enantiomer of Voriconazole. An antifungal (systemic). An ergosterol biosynthesis inhibitor.
35 supplier list of "rel-(R,R)-Voriconazole"
- Product Name:Voriconazole
- Products Intro:Purity: 99.99% | Package: 1g
- Company Type: Trader
- Country/Region: CHINA
- Product Name:Voriconazole Impurity 6
- Products Intro:Purity: 98% HPLC | Package: 10mg;25mg;50mg;100mg | CustNote: COA, 1H NMR, MS, and HPLC purity data provided with shipment.
- Company Type: Trader
- Country/Region: CHINA
- Main Products: Tadalafil Spiro-urethane Impurity(EP Impurity F),Acarbose EP Impurity H,Metoclopramide Impurity 15,Vitamin B6 Impurity 14 HCl,Tocopherol EP Impurity E
- Product Name:Voriconazole USP Related Compound A
- Products Intro:Purity: 0.95 | Package: 10mg; 25mg;50mg;100mg | CustNote: Brand: QCS; Can provide COA, hydrogen spectrum, mass spectrometry, liquid phase; Level: Pharmaceutical Impurity Standard
- Company Type: Trader
- Country/Region: CHINA
- Main Products: Rivaroxaban,Dapoxetine,Avatrombopag,Upadacitinib,Isavuconazole
You can find rel-(R,R)-Voriconazole suppliers,
manufacturers, and distributors from countries such as CHINA, United States and the Europe here.
Browse to the tetrahydrofuran product information displayed by the supplier,
as well as the supplier's contact and capability information.








